TRANSPLANT Act of 2020

Bill: 116-hr-4764
Sponsor: full_name: Rep. Matsui, Doris O. [D-CA-6]
Introduced: 2019-10-18
Policy area: Health
Subjects: Advisory bodies

Blood and blood diseases

Cell biology and embryology

Congressional oversight

Government studies and investigations

Health programs administration and funding

Medical research

Organ and tissue donation and transplantation

Research administration and funding
Latest action: action_date: 2020-12-14
text: Message on Senate action sent to the House.

Summaries:
action_date: 2019-10-18
action_desc: Introduced in House
text: <p><b>Timely ReAuthorization of Necessary Stem-cell Programs Lends Access to Needed Therapies Act of 2019 or the TRANSPLANT Act of 2019</b><br> <br> This bill modifies and reauthorizes through FY2025 the C.W. Bill Young Cell Transplantation Program, which provides support to patients who need a potentially life-saving bone marrow transplant or umbilical cord blood transplant. The bill also requires the Department of Health and Human Services to conduct a periodic review of the science of using adult stem cells and birthing tissues in therapeutic treatments.</p>

action_date: 2020-09-29
action_desc: Reported to House
text: <p><b>Timely ReAuthorization of Necessary Stem-cell Programs Lends Access to Needed Therapies Act of 2019 or the TRANSPLANT Act of 2019</b><br> <br> This bill modifies and reauthorizes through FY2025 the C.W. Bill Young Cell Transplantation Program, which provides support to patients who need a potentially life-saving bone marrow transplant or umbilical cord blood transplant. The bill also requires the Department of Health and Human Services to conduct a periodic review of the science of using adult stem cells and birthing tissues in therapeutic treatments.</p>

action_date: 2020-09-30
action_desc: Passed House
text: <p><b>Timely ReAuthorization of Necessary Stem-cell Programs Lends Access to Needed Therapies Act of 2020 or the TRANSPLANT Act of 2020</b><br> <br> This bill modifies and reauthorizes through FY2025 the C.W. Bill Young Cell Transplantation Program, which provides support to patients who need a potentially life-saving bone marrow transplant or umbilical cord blood transplant. It also requires research and other activities related to stem cell therapies.</p> <p>Specifically, the Department of Health and Human Services must conduct a periodic review of the science of using adult stem cells and birthing tissues in therapeutic treatments, and the National Institutes of Health must continue efforts to further the field of regenerative medicine using adult stem cells.</p> <p>In addition, the Government Accountability Office must examine various issues related to the national blood stem cell workforce. <p>

action_date: 2020-12-11
action_desc: Passed Senate
text: <p><b>Timely ReAuthorization of Necessary Stem-cell Programs Lends Access to Needed Therapies Act of 2020 or the TRANSPLANT Act of 2020</b><br> <br> This bill modifies and reauthorizes through FY2025 the C.W. Bill Young Cell Transplantation Program, which provides support to patients who need a potentially life-saving bone marrow transplant or umbilical cord blood transplant. It also requires research and other activities related to stem cell therapies.</p> <p>Specifically, the Department of Health and Human Services must conduct a periodic review of the science of using adult stem cells and birthing tissues in therapeutic treatments, and the National Institutes of Health must continue efforts to further the field of regenerative medicine using adult stem cells.</p> <p>In addition, the Government Accountability Office must examine various issues related to the regenerative medicine workforce. <p> <p>

tv_txt: I 116th CONGRESS 1st Session H. R. 4764 IN THE HOUSE OF REPRESENTATIVES October 18, 2019 Ms. Matsui (for herself, Mr. Bilirakis , and Ms. Pingree ) introduced the following bill; which was referred to the Committee on Energy and Commerce A BILL To reauthorize the Stem Cell Therapeutic and Research Act of 2005, and for other purposes.

1. Short title This Act may be cited as the Timely ReAuthorization of Necessary Stem-cell Programs Lends Access to Needed Therapies Act of 2019 or the TRANSPLANT Act of 2019 . 2. Reauthorization of the C.W. Bill Young Cell Transplantation Program (a) Advisory council meetings Subsection (a) of section 379 of the Public Health Service Act ( 42 U.S.C. 274k ) is amended by adding at the end the following new paragraph: (7) The Secretary shall convene the Advisory Council at least two times each calendar year. . (b) Increasing collection (1) Technical clarification Effective as if included in the enactment of Public Law 114–104 (the Stem Cell Therapeutic and Research Reauthorization Act of 2015), the amendment to section 379(d)(2)(B) of the Public Health Service Act ( 42 U.S.C. 274k(d)(2)(B) ) in section 2(a)(2) of Public Law 114–104 is amended by inserting goal of increasing collections of high quality before cord blood units, . (2) Eliminating deadwood Subparagraph (B) of section 379(d)(2) of the Public Health Service Act ( 42 U.S.C. 274k(d)(2) ) is amended by striking the second and third sentences in such subparagraph. (c) Periodic review of state of science Section 379 of the Public Health Service Act ( 42 U.S.C. 274k ) is amended by adding at the end the following new subsection: (o) Periodic review of state of science (1) Review Not less than every two years, the Secretary, in consultation with the Director of the National Institutes of Health, the Commissioner of Food and Drugs, the Administrator of the Health Resources and Services Administration, the Advisory Council, and other stakeholders, where appropriate given relevant expertise, shall conduct a review of the state of the science of using adult stem cells and birthing tissues to develop new types of therapies for patients, for the purpose of considering the potential inclusion of such new types of therapies in the Program. (2) Recommendations Not later than June 30, 2024, the Secretary shall— (A) complete the second review required by paragraph (1); and (B) informed by such review, submit to the Committee on Health, Education, Labor, and Pensions of the Senate and the Committee on Energy and Commerce of the House of Representatives recommendations on the appropriateness of the inclusion of new types of therapies in the Program. . (d) Authorization of appropriations Section 379B of the Public Health Service Act ( 42 U.S.C. 274m ) is amended by striking $33,000,000 for fiscal year 2015 and $30,000,000 for each of fiscal years 2016 through 2020 and inserting $30,000,000 for each of fiscal years 2021 through 2025 . 3. Cord blood inventory Subsection (g) of section 2 of the Stem Cell Therapeutic and Research Act of 2005 ( 42 U.S.C. 274k note) is amended to read as follows: (g) Authorization of appropriations To carry out this section, there is authorized to be appropriated $23,000,000 for each of fiscal years 2021 through 2025. .

tv_txt: I 116th CONGRESS 2d Session H. R. 4764 IN THE HOUSE OF REPRESENTATIVES AN ACT To reauthorize the Stem Cell Therapeutic and Research Act of 2005, and for other purposes.

1. Short title This Act may be cited as the Timely ReAuthorization of Necessary Stem-cell Programs Lends Access to Needed Therapies Act of 2020 or the TRANSPLANT Act of 2020 . 2. Reauthorization of the C.W. Bill Young Cell Transplantation Program (a) Advisory council meetings Subsection (a) of section 379 of the Public Health Service Act ( 42 U.S.C. 274k ) is amended by adding at the end the following new paragraph: (7) The Secretary shall convene the Advisory Council at least two times each calendar year. . (b) Increasing collection (1) Technical clarification Effective as if included in the enactment of Public Law 114–104 (the Stem Cell Therapeutic and Research Reauthorization Act of 2015), the amendment to section 379(d)(2)(B) of the Public Health Service Act ( 42 U.S.C. 274k(d)(2)(B) ) in section 2(a)(2) of Public Law 114–104 is amended by inserting goal of increasing collections of high quality before cord blood units, . (2) Eliminating deadwood Subparagraph (B) of section 379(d)(2) of the Public Health Service Act ( 42 U.S.C. 274k(d)(2) ) is amended by striking the second and third sentences in such subparagraph. (c) Periodic review of state of science Section 379 of the Public Health Service Act ( 42 U.S.C. 274k ) is amended by adding at the end the following new subsection: (o) Periodic review of state of science (1) Review Not less than every two years, the Secretary, in consultation with the Director of the National Institutes of Health, the Commissioner of Food and Drugs, the Administrator of the Health Resources and Services Administration, the Advisory Council, and other stakeholders, where appropriate given relevant expertise, shall conduct a review of the state of the science of using adult stem cells and birthing tissues to develop new types of therapies for patients, for the purpose of considering the potential inclusion of such new types of therapies in the Program. (2) Recommendations Not later than June 30, 2024, the Secretary shall— (A) complete the second review required by paragraph (1); and (B) informed by such review, submit to the Committee on Health, Education, Labor, and Pensions of the Senate and the Committee on Energy and Commerce of the House of Representatives recommendations on the appropriateness of the inclusion of new types of therapies in the Program. . (d) Authorization of appropriations Section 379B of the Public Health Service Act ( 42 U.S.C. 274m ) is amended by striking $33,000,000 for fiscal year 2015 and $30,000,000 for each of fiscal years 2016 through 2020 and inserting $30,000,000 for each of fiscal years 2021 through 2025 . 3. Cord blood inventory Subsection (g) of section 2 of the Stem Cell Therapeutic and Research Act of 2005 ( 42 U.S.C. 274k note) is amended to read as follows: (g) Authorization of appropriations To carry out this section, there is authorized to be appropriated $23,000,000 for each of fiscal years 2021 through 2025. . 4. Advancing the field of regenerative medicine Section 402 of the Public Health Service Act ( 42 U.S.C. 282 ) is amended by adding at the end the following: (o) Regenerative Medicine The Director of NIH shall, as appropriate, continue to consult with the directors of relevant institutes and centers of the National Institutes of Health, other relevant experts from such institutes and centers, and relevant experts within the Food and Drug Administration, to further the field of regenerative medicine using adult stem cells, including autologous stem cells, therapeutic tissue engineering products, human cell and tissue products, human gene therapies, and genetically modified cells. . 5. GAO report on regenerative medicine workforce Not later than 2 years after the date of enactment of this Act, the Comptroller General of the United States shall submit to the Committee on Health, Education, Labor, and Pensions of the Senate and the Committee on Energy and Commerce of the House of Representatives a report that assesses the national blood stem cell workforce, including those related to the C.W. Bill Young Cell Transplantation Program established under section 379 of the Public Health Service Act ( 42 U.S.C. 274k ). The report shall include— (1) an overview of the current employment levels, in both commercial and academic settings, for— (A) positions necessary for the collection and transplantation of stem cell therapeutics, including bone marrow and cord blood; (B) positions in the field of regenerative medicine using adult stem cells and related to product development; and (C) Federal funding for extramural stem cell programs; (2) an overview of the current employment levels in Federal stem cell programs, including the scope of, staffing models of, and vacancies within such programs; (3) the identification of gaps, if any, in the projected workforce capacity for— (A) positions described in paragraph (1)(A); and (B) the field of regenerative medicine using adult stem cells, including workforce gaps related to the development of new cellular therapies using adult stem cells; (4) an overview of the availability of training programs related to the development, refinement, and utilization of adult stem cells, including training on good manufacturing practices for such activities, and the performance of such programs; and (5) recommendations, if any, for improving the workforce capacity related to— (A) the positions described in paragraph (1)(A); or (B) the field of regenerative medicine using adult stem cells.

Passed the House of Representatives September 30, 2020. Cheryl L. Johnson, Clerk.

tv_txt: IB Union Calendar No. 449 116th CONGRESS 2d Session H. R. 4764 [Report No. 116–549] IN THE HOUSE OF REPRESENTATIVES October 18, 2019 Ms. Matsui (for herself, Mr. Bilirakis , and Ms. Pingree ) introduced the following bill; which was referred to the Committee on Energy and Commerce September 29, 2020 Additional sponsors: Mr. Fitzpatrick , Ms. Jackson Lee , Mr. Budd , Mr. Aderholt , Mr. Walden , Mr. Swalwell of California , Mr. Hastings , Mr. Neguse , Mr. Young , Mr. Welch , Mr. Brown of Maryland , Mr. Rouda , Mr. Butterfield , Mr. Crist , Mr. Lowenthal , Mr. Schrader , Mr. Harder of California , Mr. Rush , Mr. Casten of Illinois , Ms. DeGette , Mrs. Axne , Mr. Cartwright , Mr. Grijalva , Mr. McGovern , Ms. Sewell of Alabama , Mr. Hudson , Mr. Waltz , Mr. Aguilar , Mrs. Beatty , Mr. Panetta , Mr. Tiffany , Mrs. Rodgers of Washington , Mr. Stanton , Ms. Omar , Mr. Heck , Mr. Trone , Ms. Craig , Mr. Suozzi , Ms. McCollum , Ms. Dean , Mrs. Napolitano , Mr. Case , Mr. Gottheimer , Mr. Emmer , Mr. Johnson of Georgia , Ms. Brownley of California , Mrs. Wagner , Mrs. Hayes , Mr. Smith of Washington , and Mrs. Murphy of Florida September 29, 2020 Reported from the Committee on Energy and Commerce ; committed to the Committee of the Whole House on the State of the Union and ordered to be printed A BILL To reauthorize the Stem Cell Therapeutic and Research Act of 2005, and for other purposes.

1. Short title This Act may be cited as the Timely ReAuthorization of Necessary Stem-cell Programs Lends Access to Needed Therapies Act of 2019 or the TRANSPLANT Act of 2019 . 2. Reauthorization of the C.W. Bill Young Cell Transplantation Program (a) Advisory council meetings Subsection (a) of section 379 of the Public Health Service Act ( 42 U.S.C. 274k ) is amended by adding at the end the following new paragraph: (7) The Secretary shall convene the Advisory Council at least two times each calendar year. . (b) Increasing collection (1) Technical clarification Effective as if included in the enactment of Public Law 114–104 (the Stem Cell Therapeutic and Research Reauthorization Act of 2015), the amendment to section 379(d)(2)(B) of the Public Health Service Act ( 42 U.S.C. 274k(d)(2)(B) ) in section 2(a)(2) of Public Law 114–104 is amended by inserting goal of increasing collections of high quality before cord blood units, . (2) Eliminating deadwood Subparagraph (B) of section 379(d)(2) of the Public Health Service Act ( 42 U.S.C. 274k(d)(2) ) is amended by striking the second and third sentences in such subparagraph. (c) Periodic review of state of science Section 379 of the Public Health Service Act ( 42 U.S.C. 274k ) is amended by adding at the end the following new subsection: (o) Periodic review of state of science (1) Review Not less than every two years, the Secretary, in consultation with the Director of the National Institutes of Health, the Commissioner of Food and Drugs, the Administrator of the Health Resources and Services Administration, the Advisory Council, and other stakeholders, where appropriate given relevant expertise, shall conduct a review of the state of the science of using adult stem cells and birthing tissues to develop new types of therapies for patients, for the purpose of considering the potential inclusion of such new types of therapies in the Program. (2) Recommendations Not later than June 30, 2024, the Secretary shall— (A) complete the second review required by paragraph (1); and (B) informed by such review, submit to the Committee on Health, Education, Labor, and Pensions of the Senate and the Committee on Energy and Commerce of the House of Representatives recommendations on the appropriateness of the inclusion of new types of therapies in the Program. . (d) Authorization of appropriations Section 379B of the Public Health Service Act ( 42 U.S.C. 274m ) is amended by striking $33,000,000 for fiscal year 2015 and $30,000,000 for each of fiscal years 2016 through 2020 and inserting $30,000,000 for each of fiscal years 2021 through 2025 . 3. Cord blood inventory Subsection (g) of section 2 of the Stem Cell Therapeutic and Research Act of 2005 ( 42 U.S.C. 274k note) is amended to read as follows: (g) Authorization of appropriations To carry out this section, there is authorized to be appropriated $23,000,000 for each of fiscal years 2021 through 2025. .

September 29, 2020 Reported from the Committee on Energy and Commerce ; committed to the Committee of the Whole House on the State of the Union and ordered to be printed

tv_txt: II 116th CONGRESS 2d Session H. R. 4764 IN THE SENATE OF THE UNITED STATES October 1, 2020 Received AN ACT To reauthorize the Stem Cell Therapeutic and Research Act of 2005, and for other purposes.

1. Short title This Act may be cited as the Timely ReAuthorization of Necessary Stem-cell Programs Lends Access to Needed Therapies Act of 2020 or the TRANSPLANT Act of 2020 . 2. Reauthorization of the C.W. Bill Young Cell Transplantation Program (a) Advisory council meetings Subsection (a) of section 379 of the Public Health Service Act ( 42 U.S.C. 274k ) is amended by adding at the end the following new paragraph: (7) The Secretary shall convene the Advisory Council at least two times each calendar year. . (b) Increasing collection (1) Technical clarification Effective as if included in the enactment of Public Law 114–104 (the Stem Cell Therapeutic and Research Reauthorization Act of 2015), the amendment to section 379(d)(2)(B) of the Public Health Service Act ( 42 U.S.C. 274k(d)(2)(B) ) in section 2(a)(2) of Public Law 114–104 is amended by inserting goal of increasing collections of high quality before cord blood units, . (2) Eliminating deadwood Subparagraph (B) of section 379(d)(2) of the Public Health Service Act ( 42 U.S.C. 274k(d)(2) ) is amended by striking the second and third sentences in such subparagraph. (c) Periodic review of state of science Section 379 of the Public Health Service Act ( 42 U.S.C. 274k ) is amended by adding at the end the following new subsection: (o) Periodic review of state of science (1) Review Not less than every two years, the Secretary, in consultation with the Director of the National Institutes of Health, the Commissioner of Food and Drugs, the Administrator of the Health Resources and Services Administration, the Advisory Council, and other stakeholders, where appropriate given relevant expertise, shall conduct a review of the state of the science of using adult stem cells and birthing tissues to develop new types of therapies for patients, for the purpose of considering the potential inclusion of such new types of therapies in the Program. (2) Recommendations Not later than June 30, 2024, the Secretary shall— (A) complete the second review required by paragraph (1); and (B) informed by such review, submit to the Committee on Health, Education, Labor, and Pensions of the Senate and the Committee on Energy and Commerce of the House of Representatives recommendations on the appropriateness of the inclusion of new types of therapies in the Program. . (d) Authorization of appropriations Section 379B of the Public Health Service Act ( 42 U.S.C. 274m ) is amended by striking $33,000,000 for fiscal year 2015 and $30,000,000 for each of fiscal years 2016 through 2020 and inserting $30,000,000 for each of fiscal years 2021 through 2025 . 3. Cord blood inventory Subsection (g) of section 2 of the Stem Cell Therapeutic and Research Act of 2005 ( 42 U.S.C. 274k note) is amended to read as follows: (g) Authorization of appropriations To carry out this section, there is authorized to be appropriated $23,000,000 for each of fiscal years 2021 through 2025. . 4. Advancing the field of regenerative medicine Section 402 of the Public Health Service Act ( 42 U.S.C. 282 ) is amended by adding at the end the following: (o) Regenerative Medicine The Director of NIH shall, as appropriate, continue to consult with the directors of relevant institutes and centers of the National Institutes of Health, other relevant experts from such institutes and centers, and relevant experts within the Food and Drug Administration, to further the field of regenerative medicine using adult stem cells, including autologous stem cells, therapeutic tissue engineering products, human cell and tissue products, human gene therapies, and genetically modified cells. . 5. GAO report on regenerative medicine workforce Not later than 2 years after the date of enactment of this Act, the Comptroller General of the United States shall submit to the Committee on Health, Education, Labor, and Pensions of the Senate and the Committee on Energy and Commerce of the House of Representatives a report that assesses the national blood stem cell workforce, including those related to the C.W. Bill Young Cell Transplantation Program established under section 379 of the Public Health Service Act ( 42 U.S.C. 274k ). The report shall include— (1) an overview of the current employment levels, in both commercial and academic settings, for— (A) positions necessary for the collection and transplantation of stem cell therapeutics, including bone marrow and cord blood; (B) positions in the field of regenerative medicine using adult stem cells and related to product development; and (C) Federal funding for extramural stem cell programs; (2) an overview of the current employment levels in Federal stem cell programs, including the scope of, staffing models of, and vacancies within such programs; (3) the identification of gaps, if any, in the projected workforce capacity for— (A) positions described in paragraph (1)(A); and (B) the field of regenerative medicine using adult stem cells, including workforce gaps related to the development of new cellular therapies using adult stem cells; (4) an overview of the availability of training programs related to the development, refinement, and utilization of adult stem cells, including training on good manufacturing practices for such activities, and the performance of such programs; and (5) recommendations, if any, for improving the workforce capacity related to— (A) the positions described in paragraph (1)(A); or (B) the field of regenerative medicine using adult stem cells.

Passed the House of Representatives September 30, 2020. Cheryl L. Johnson, Clerk

tv_txt: 116th CONGRESS 2d Session H.R. 4764 In the Senate of the United States, December 11, 2020. Amendment:

That the bill from the House of Representatives (H.R. 4764) entitled An Act to reauthorize the Stem Cell Therapeutic and Research Act of 2005, and for other purposes. , do pass with the following Strike all after the enacting clause and insert the following: 1. Short title This Act may be cited as the Timely ReAuthorization of Necessary Stem-cell Programs Lends Access to Needed Therapies Act of 2020 or the TRANSPLANT Act of 2020 . 2. Reauthorization of the C.W. Bill Young Cell Transplantation Program (a) Advisory council meetings Subsection (a) of section 379 of the Public Health Service Act ( 42 U.S.C. 274k ) is amended by adding at the end the following new paragraph: (7) The Secretary shall convene the Advisory Council at least two times each calendar year. . (b) Increasing collection (1) Technical clarification Effective as if included in the enactment of Public Law 114–104 (the Stem Cell Therapeutic and Research Reauthorization Act of 2015), the amendment to section 379(d)(2)(B) of the Public Health Service Act ( 42 U.S.C. 274k(d)(2)(B) ) in section 2(a)(2) of Public Law 114–104 is amended by inserting goal of increasing collections of high quality before cord blood units, . (2) Eliminating deadwood Subparagraph (B) of section 379(d)(2) of the Public Health Service Act ( 42 U.S.C. 274k(d)(2) ) is amended by striking the second and third sentences in such subparagraph. (c) Periodic review of state of science Section 379 of the Public Health Service Act ( 42 U.S.C. 274k ) is amended by adding at the end the following new subsection: (o) Periodic review of state of science (1) Review Not less than every two years, the Secretary, in consultation with the Director of the National Institutes of Health, the Commissioner of Food and Drugs, the Administrator of the Health Resources and Services Administration, the Advisory Council, and other stakeholders, where appropriate given relevant expertise, shall conduct a review of the state of the science of using adult stem cells and birthing tissues to develop new types of therapies for patients, for the purpose of considering the potential inclusion of such new types of therapies in the Program. (2) Recommendations Not later than June 30, 2024, the Secretary shall— (A) complete the second review required by paragraph (1); and (B) informed by such review, submit to the Committee on Health, Education, Labor, and Pensions of the Senate and the Committee on Energy and Commerce of the House of Representatives recommendations on the appropriateness of the inclusion of new types of therapies in the Program. . (d) Authorization of appropriations Section 379B of the Public Health Service Act ( 42 U.S.C. 274m ) is amended by striking $33,000,000 for fiscal year 2015 and $30,000,000 for each of fiscal years 2016 through 2020 and inserting $30,000,000 for each of fiscal years 2021 through 2025 . 3. Cord blood inventory Subsection (g) of section 2 of the Stem Cell Therapeutic and Research Act of 2005 ( 42 U.S.C. 274k note) is amended to read as follows: (g) Authorization of appropriations To carry out this section, there is authorized to be appropriated $23,000,000 for each of fiscal years 2021 through 2025. . 4. Advancing the field of regenerative medicine Section 402 of the Public Health Service Act ( 42 U.S.C. 282 ) is amended by adding at the end the following: (o) Regenerative Medicine The Director of NIH shall, as appropriate, continue to consult with the directors of relevant institutes and centers of the National Institutes of Health, other relevant experts from such institutes and centers, and relevant experts within the Food and Drug Administration, to further the field of regenerative medicine using adult stem cells, including autologous stem cells, therapeutic tissue engineering products, human cell and tissue products, human gene therapies, and genetically modified cells. . 5. GAO report on regenerative medicine workforce Not later than 2 years after the date of enactment of this Act, the Comptroller General of the United States shall submit to the Committee on Health, Education, Labor, and Pensions of the Senate and the Committee on Energy and Commerce of the House of Representatives a report that assesses a specialized health care workforce in the field of regenerative medicine. The report shall include— (1) an overview of the current employment levels, in both commercial and academic settings, for— (A) positions necessary for the collection and transplantation of stem cell therapeutics, including bone marrow and cord blood; and (B) positions in the field of regenerative medicine using adult stem cells and related to product development; (2) the identification of gaps, if any, in the projected workforce capacity for— (A) positions described in paragraph (1)(A); and (B) the field of regenerative medicine using adult stem cells, including workforce gaps related to the development of new cellular therapies using adult stem cells; (3) an overview of the availability of training programs related to the development, refinement, and utilization of adult stem cells, including training on good manufacturing practices for such activities, and the performance of such programs; and (4) recommendations, if any, for improving the workforce capacity related to— (A) the positions described in paragraph (1)(A); or (B) the field of regenerative medicine using adult stem cells.

Secretary